By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Oncology have been published. According to news reporting originating from Stony Brook, New York, by NewsRx correspondents, research stated, "Phospho-sulindac (PS) is a safe sulindac derivative with promising anticancer efficacy in colon cancer. We evaluated whether its combination with curcumin could enhance the efficacy in the treatment of lung cancer."
Our news editors obtained a quote from the research from the State University of New York, "Curcumin, the principal bioactive component in turmeric, has demonstrated versatile capabilities to modify the therapeutic efficacy of a wide range of anticancer agents. Here, we evaluated the effect of co-administration of curcumin on the anticancer activity of PS in a mouse xenograft model of human lung cancer. Curcumin enhanced the cellular uptake of PS in human lung and colon cancer cell lines. To assess the potential synergism between curcumin and PS in vivo, curcumin was suspended in 10% Tween-80 or formulated in micellar nanoparticles and given to mice by oral gavage prior to the administration of PS. Both formulations of curcumin significantly improved the pharmacokinetic profiles of PS, with the 10% Tween-80 suspension being much more effective than the nanoparticle formation. However, curcumin did not exhibit any significant modification of the metabolite profile of PS. Furthermore, in a mouse subcutaneous xenograft model of human lung cancer, PS (200 mg/kg) in combination with curcumin (500 mg/kg) suspended in 10% Tween-80 (51% inhibition, p
According to the news editors, the research concluded: "Our results show that curcumin substantially improves the pharmacokinetics of PS leading to synergistic inhibition of the growth of human lung cancer xenografts, representing a promising drug combination."
For more information on this research see: Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics. International Journal of Oncology, 2013;43(3):895-902. International Journal of Oncology can be contacted at: Spandidos Publ Ltd, Pob 18179, Athens, 116 10, Greece (see also Oncology).
The news editors report that additional information may be obtained by contacting K.W. Cheng, SUNY Stony Brook, Canc Prevent Div, Dept. of Med, Stony Brook, NY 11794, United States. Additional authors for this research include C.C. Wong, G. Mattheolabakis, G. Xie, L.Q. Huang and B. Rigas.
Keywords for this news article include: Pharmaceuticals, Drugs, New York, Oncology, Treatment, Stony Brook, Lung Cancer, Therapeutics, United States, Lung Neoplasms, Pharmacokinetics, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC